Data gathered: December 21
AI Stock Analysis - Novo Nordisk (NVO)
Analysis generated December 21, 2024. Powered by Chat GPT.
Novo Nordisk (NYSE: NVO) is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also holds a leading position within areas such as obesity care, hemophilia, growth disorders, and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk operates in countries around the globe and employs more than 43,000 people globally.
Stock Alerts - Novo Nordisk (NVO)
 |
Novo Nordisk | December 20 Price is down by -20.2% in the last 24h. |
|
Novo Nordisk | December 20 Trending on Reddit. |
|
Novo Nordisk | December 19 Michael McCaul (member of U.S. congress) is selling shares |
|
Novo Nordisk | December 10 Over the past few months, there has been an upward trend in Web Traffic. |
Alternative Data for Novo Nordisk
About Novo Nordisk
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents.
| Price | $85.00 |
| Target Price | Sign up |
| Volume | 53,690,000 |
| Market Cap | $482B |
| Year Range | $85 - $146.35 |
| Dividend Yield | 1.4% |
| PE Ratio | 34.71 |
| Analyst Rating | 57% buy |
| Industry | Drug Manufacturers |
In the news
 |
BMO lowers Novo Nordisk price target to $105, says reaction to data 'overdone'December 20 - Thefly.com |
 |
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are UpDecember 20 - Biztoc.com |
 |
Novo Nordisk Stock Plummets: Bearish Signals Dominate After Drug Trial MissDecember 20 - Biztoc.com |
 |
What Novo Nordisk’s disappointing trial results mean for the obesity drug marketDecember 20 - STAT |
 |
Novo Nordisk shares plummet after weight-loss drug’s disappointing trial resultsDecember 20 - New York Post |
European markets close lower; Novo Nordisk down 20% after obesity drug results - CNBCDecember 20 - Slashdot.org |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 71.3B | 11.3B | 60B | 27.3B | 37.4B | 0.900 |
| Q2 '24 | 68.1B | 10.3B | 57.8B | 20.1B | 34.8B | 0.660 |
| Q1 '24 | 65.3B | 9.92B | 55.4B | 25.4B | 35.3B | 0.830 |
| Q4 '23 | 65.9B | 10B | 55.8B | 22B | 28.5B | 0.710 |
| Q3 '23 | 58.7B | 9.71B | 49B | 22.5B | 29.4B | 0.730 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$144.47 0% | 40 |
 |
Eli Lilly and CompanyLLY |
$767.76 0% | 61 |
 |
PfizerPFE |
$26.36 0% | 37 |
 |
AstrazenecaAZN |
$65.35 0% | 54 |
 |
AbbVieABBV |
$175.58 0% | 60 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Michael McCaul |
Dec 18, 24 | Sell | $50K - $100K |
| Michael McCaul |
Nov 14, 24 | Buy | $15K - $50K |
| John James |
Sep 2, 24 | Buy | $1K - $15K |
Read more about Novo Nordisk (NVO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Novo Nordisk?
The Market Cap of Novo Nordisk is $482B.
What is Novo Nordisk's PE Ratio?
As of today, Novo Nordisk's PE (Price to Earnings) ratio is 34.71.
What is the current stock price of Novo Nordisk?
Currently, the price of one share of Novo Nordisk stock is $85.00.
How can I analyze the NVO stock price chart for investment decisions?
The NVO stock price chart above provides a comprehensive visual representation of Novo Nordisk's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Novo Nordisk shares. Our platform offers an up-to-date NVO stock price chart, along with technical data analysis and alternative data insights.
Does NVO offer dividends to its shareholders?
Yes, Novo Nordisk (NVO) offers dividends to its shareholders, with a dividend yield of 1.4%. This dividend yield represents Novo Nordisk's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Novo Nordisk in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Novo Nordisk?
Some of the similar stocks of Novo Nordisk are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.